Infant RSV mRNA Injection Trials Paused Due to Safety Concerns

.

The FDA has just released a briefing document for the December 12, 2024, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting titled, Considerations for Respiratory Syncytial Virus (RSV) Vaccine Safety in Pediatric Populations. 

The document revealed that, in July 2024, a Phase 1 trial assessing the safety, tolerability, and immunogenicity of two Moderna RSV vaccine candidates (mRNA-1365 and mRNA-1345) in infants aged 5 to 8 months was paused following reports of five severe to very severe cases of lower respiratory tract infection (LRTI) caused by RSV:

During the study, an imbalance in severe RSV cases was identified, based on a pre-specified study stopping criterion, among participants 5 months through <8 months of age who received the lower mRNA vaccine dose. In Cohorts 3 and 4, five (5) cases (12.5% of participants) of clinically significant (CS) severe/very severe RSV were identified in the vaccine groups (all of whom had received 1 or 2 doses of a 3-dose schedule), compared with one (1) case (5% of participants) in the placebo group. The percentage of participants with symptomatic RSV disease in Cohorts 3 and 4 who progressed to severe illness was 26.3% in the vaccine groups compared with 8.3% in the placebo group.

Of the six total severe cases (including one in the placebo group), five infants required hospitalization, and one required mechanical ventilation. The specific case details are presented in the following table:

One of the candidates in the paused trial was mRNA-1345 (mRESVIA), which had already been approved by the FDA for adults aged 60 and older, despite the absence of genotoxicity, oncogenicity, or long-term safety studies:

BREAKING–Moderna Receives U.S. FDA Approval for mRNA RSV Vaccine mRESVIA(R)

Peter A. McCullough, MD, MPH

·

3 June

By Peter A. McCullough, MD, MPH

Read full story

This is yet another instance of mRNA injections failing to meet essential safety requirements. Rather than protecting infants from RSV, these novel injections seem to have worsened the severity of infections.

Instead of persisting with the development and rollout of this flawed mRNA platform, our public health agencies should prioritize interventions that do not commonly result in serious adverse events.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Source

Featured image source: https://pediatrixmd.com/health/always-call-for-sick-kids/

************

••••

The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)

••••

Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.

••••

Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.

••••

Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.